Abstract: A cognitive impairment ameliorant is provided that is useful for the prevention or treatment of cognitive impairment, and particularly Alzheimer's disease. The cognitive impairment ameliorant contains royal jelly as an active ingredient thereof.

Abstract: The invention concerns novel substituted 1,3-diphenylprop-2-en-1-one derivatives, pharmaceutical compositions comprising same, their therapeutic uses, in particular for treating cerebral ischemia. The invention also concerns a method for preparing said derivatives.

Abstract: Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.

Abstract: Use of a racemate of pinocembrin, a racemate of pinocembrin salt, a racemate of pinocembrin precursor or a racemate of pinocembrin hydrate in manufacture of a medicament for prophylaxis and treatment of stroke. Particularly, use of pinocembrin racemate in manufacture of a medicament for treatment of acute ischemic stroke.

Abstract: The present invention provides transient receptor potential vanilloid (TRPV) modulators of formula (I). In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPV3. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPV3.

Abstract: Disclosed herein is a skin external composition for inhibiting epidermal hyperproliferation and alleviating inflammatory skin diseases, which contains ortho-dihydroxyisoflavone derivatives as an active ingredient. Specifically, the skin external external composition contains the ortho-dihydroxyisoflavone derivatives, 4?,6,7-trihydroxyisoflavone, 3?,4?,7-trihydroxyisoflavone or a mixture thereof, and thus increases the expression of DKK3 protein and FZD1 protein, which appropriately control Wnt signaling, thereby inhibiting epidermal hyperproliferation and alleviating inflammatory skin diseases caused by epidermal hyperproliferation.

Abstract: Novel flavonoid compounds having anti-oxidant activity are described. The compounds and compositions have been shown to exhibit anti-oxidant properties and are particularly useful in the treatment of ischemia and reperfusion injuries. The invention also describes a method to chemically synthesize such flavonoid compounds and test their efficacy. Such compounds and corresponding pharmaceutically acceptable derivatives and/or salts have uses in the areas of pharmaceuticals, nutraceutical, and veterinary applications.

Abstract: Therapeutic method of treatment, compositions and foodstuffs are described which contain isoflavone compounds described by general formula (I), in which Z is H, R1 is H or RACO wherein Ra is C1-10alkyl or an amino acid, R2 is H, OH or ORB where RB is an amino acid, or CORA where RA is as previously defined, W is H, A is H or OH, and B is selected from (a), (b), (c) or W is H, and A and B taken together form a six-membered ring selected from (d), or W, A and B taken with the groups with which they are associated comprise (f) and B is (g) where R3 is H, CORA where RA is as previously defined, CO2RC where RC is C1-10alkyl, or CORB where RB is as previously defined, R4 is H, CORD where RD is H, OH, C1-10alkyl or an amino acid, CO2RC where RC is as previously defined, CORE where RE is H, C1-10alkyl or an amino acid, COOH, CORC where RC is as previously defined, or CONHRE where RE is as previously defined, R5 is H, CO2RC where RC is as previously defined, or CORCORE where RC and RE are as previously defined, an

Abstract: Two crystalline forms of pinocembrin of formula (I): ? and ?, their preparation and their use for manufacture of pharmaceutical compositions. There exists difference between them in bioavailability. They are used for treating and preventing cerebral ischemic diseases by protective action of neurovascular unit, and enhancing blood drug level in vivo.

Abstract: The invention relates to a compound represented by the following formula (I): and pharmaceutically acceptable salts, stereoisomers, enantiomers, prodrugs and solvates thereof. The compounds are useful as an agent for enhancing the neurite outgrowth and preventing or treating of diseases associated with HDAC in particular, tumor or cell proliferative diseases. In particular, the compounds of the invention can be used as an agent for anti-neurodegenerative diseases and human spinal muscular atrophy (SMA).

Abstract: This invention relates to a biologically active formulation containing a conjugate of a fatty acid and a complex phenol. The fatty acid can be selected from a variety of fatty acids including acids have between 12 and 24 carbon atoms. The phenol can be a polynuclear phenol, a polyphenol or a polyfunctional phenol having a variety of substituents. The formulation can include pharmaceutically acceptable carrier, including diluent. The formulation can be provided in an active dosage form suitable to inhibit mammalian cell growth and/or metastasis of malignant cells. The formulation can be used to induce cytotoxicity in mammalian cells particularly tumor cells or to treat and prevent cellular injury or dysfunction.

Abstract: A biocompatible polymer composition which includes a matrix material and at least one of an isoflavone and a flavone at least partially dispersed in the matrix material is suited to use in a membrane for hemodialysis and other in vivo and in vitro applications.

Abstract: Novel pyrone analogs are described which can enhance the effectiveness of a therapeutic agent when administered and/or reduce side effects caused by the administration of a therapeutic agent.

Abstract: The invention concerns novel substituted 1,3-diphenylprop-2-en-1-one derivatives, pharmaceutical compositions comprising same, their therapeutic uses, in particular for treating cerebral ischemia. The invention also concerns a method for preparing said derivatives.

Abstract: Methods, uses, compositions and kits relating to the inhibition and/or prevention of undesirable cell proliferation, and prevention and/or treatment of diseases or disorders associated with such proliferation, such as cancer, using a cytosine nucleoside analog such as 5-aza-2?-deoxycytidine and an isoflavone such as genistein, are described.

Abstract: Compounds of general formula (I) and (II) in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14 and R15 have the meanings given in the specification, are useful in the treatment of neurodegenerative disease.

Abstract: Novel compounds and methods related to the activation of the TrkB receptor are provided. The methods include administering in vivo or in vitro a therapeutically effective amount of 7,8-dihydroxyflavone or derivative thereof. Specifically, methods and compounds for the treatment of disorders including neurologic disorders, neuropsychiatric disorders, and metabolic disorders (e.g., obesity) are provided. For example, a first method is provided of treating or reducing the risk of depression, anxiety, or obesity in a subject, which includes selecting a subject with or at risk of developing depression, anxiety, or obesity, and administering to the subject a therapeutically effective amount of 7,8-dihydroxyflavone or a derivative thereof. A further method of promoting neuroprotection in a subject also is provided, which includes selecting a subject in need of neuroprotection, and administering to the subject a therapeutically effective amount of 7,8-dihydroxyflavone or a derivative thereof.

Abstract: A method for preparing an enantiomeric chromane, by asymmetrically hydrogenating a chromene compound in the presence of an Ir catalyst having a chiral ligand. The method includes the enantioselective preparation of enantiomeric equol. A preferred Ir catalyst has a chiral phosphineoxazoline ligand. Enantiomeric chromanes of high stereoselective purity can be obtained.

Abstract: The present invention relates to a compound of the formula: R-AR—O—Y—R? Wherein R represents one or more members selected from H, alkoxy, benzyloxy, aldehyde, halogen, carboxylic acid, —NO2, —NH2, —NHCOCH3, and —NH—Y—R?, which is attached directly to AR or attached through an aliphatic chain. The carboxylic acid moiety in R includes but is not limited to the following carboxylic acids: benzoic acids, cinnamic acids, ferulic acid, caffeic acid, syringic acid, salicyclic acid, vanillic acid, phenylacetic acids, phenylpropionic acids, and sinapinic acid. -AR—O— is a biologically active phenolic moiety comprising 1 to 6 substituted or unsubstituted aryl rings that are directly bonded to each other, fused together, or joined through a linking group.

Abstract: Various chromanone, flavanone and abyssinone compounds as can be prepared enantioselectively using a chiral thiourea catalyst.

Abstract: The present invention provides PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.

Abstract: The present invention provides an optically active compound of general formula (I) and salts thereof: wherein R? is selected from a group consisting of t-butyl amine, n-butylamine, iso-butylamine, iso-propyl amine, 4-phenyl-piperazine-1-ylamine, 4-(2-methoxyphenyl)-piperazin-1-ylamine, and 3,4-dimethoxy phenethyl amine; wherein R1, R2 and R3 are selected from the group consisting of hydrogen, methyl or iso pentenyl; R4, R5 and R6 are selected from the group consisting of Oil, O-alkyl, O-benzyl, O-substituted phenyl or combination thereof.

Abstract: An isoflavone derivative of tectorigenin compound as shown in formula (II), its preparation method and the antiviral medicine containing it as an effective constituent. The compound structure is shown as follows: Where:: R1 is H, NH2 or SO3M; R2 is OR?; R3 is H or —CH2NR?; where R? is H, —CH2COONa or —CH2CH2NMe2; NR? is or —NMe2; M is H, Na, K or N+H (CH2CH2OH)3.

Abstract: Described herein are flavonoids (e.g., 5-desoxy flavones and/or 5-desoxy flavonols, including without limitation fisetin and its derivatives) that activate ERK and induce CREB phosphorylation in neuronal cultures, facilitate long-term potentiation in hippocampal slices and enhance object recognition in vivo. Methods of using these flavonoids, for instance, for enhancing memory are described.

Abstract: Disclosed here in are compounds and methods of diagnosing Alzheimer's Disease or a predisposition thereto in a mammal, the method comprising administering to the mammal a diagnostically effective amount of a radiolabeled compound, wherein the compound is selected from the group consisting of radiolabeled flavones, coumarins, carbazoles, quinolinones, chromenones, imidazoles and triazoles derivatives, allowing the compound to distribute into the brain tissue, and imaging the brain tissue, wherein an increase in binding of the compound to the brain tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing Alzheimer's Disease

Abstract: The present invention provides novel Quercetin derivatives of formula (I) and pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1 is hydrogen, benzyl or substituted benzyl; R2 is hydrogen, benzyl or substituted benzyl, linear or branched (C1-C6) alkyl, substituted alkyl, aryl, substituted aryl, heterocycle and substituted heterocycle, useful for treatment of various disorders including cancer, multi-drug resistant cancers, viral infections etc. The invention also provides a process for the preparation of compounds of formula (I) and pharmaceutical compositions comprising the same.

Abstract: Disclosed herein are processes for the preparation of isoflavonoids, in particular haginin E, equol, daidzein, formononetin and the like, in which 7-benzyloxy-3-(4-methoxyphenyl)-2H-1-benzopyran is used as a common starting material.

Abstract: A growth inhibitor of bacteria of the genus Legionella contains as an active ingredient a Macaranga tanarius extract extracted from Macaranga tanarius with an extraction solvent including at least an organic solvent. Alternatively, the growth inhibitor of bacteria of the genus Legionella contains as an active ingredient at least one selected from nymphaeol-A, nymphaeol-B, and nymphaeol-C. The growth inhibitor of bacteria of the genus Legionella is used by being blended to, for example, a bath agent or a cleaning agent.

Abstract: 2-aryl and 2-heteroaryl 4h-1-benzopyran-4-one-6-amidino derivatives of formula (I) useful as pharmacological agents for the treatment of arthritis, cancer and related pain.

Abstract: The disclosure relates to a new crystalline form of genistein. The disclosed crystalline form is crystalline genistein sodium salt dihydrate. The disclosure also relates to the novel genistein salt composition represented by this crystalline form. Therapeutic compositions containing crystalline genistein sodium salt and a pharmaceutically acceptable carrier are described. The disclosure also relates to therapeutic methods comprising the step of administering to a patient in need thereof a therapeutically effective amount of a therapeutic composition containing the crystalline form of the disclosure or crystalline genistein sodium salt dihydrate.

Abstract: Various chromanone, flavanone and abyssinone compounds as can be prepared enantioselectively using a chiral thiourea catalyst.

Abstract: A pharmaceutical composition having a cytotoxic effect to a cancer cell is provided. The pharmaceutical composition includes a flavonoid compound having a formula as wherein B ring is a 4-oxo-cyclohexa-2,5-dienyl group, and any one of R1-R12 is one selected from a group consisting of hydrogen group, hydroxyl group, C1-C20 alkyl group, C1-C20 ether group, C1-C20 ester group, carboxyl group, halogen and sugar. The flavonoid compound is obtained from a chemical method being one of a total synthesis method and a semi-synthesis method.

Abstract: The present invention is directed to novel benzopyran derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders related to potassium channel.

Abstract: This invention discloses the method for preparing desmosdumotin C, the series of desmosdumotin C derivatives and their manufactures, and the total synthesis of desmosdumotin B. The invention also discloses uses of the derivatives and pharmaceutical compositions containing the same in preparation of medicines for treatment of tumor or AIDS.

Abstract: Each of an antioxidant, an antimicrobial agent, an antitumor agent, a food and beverage product, cosmetics, a quasi-drug and a pharmaceutical of the present invention contains a new flavanone compound represented by the following structural formula: Alternatively, each of an antioxidant, an antimicrobial agent, an antitumor agent, a food and beverage product, cosmetics, a quasi-drug and a pharmaceutical of the present invention contains at least one flavanone compound selected from the group consisting of nymphaeol-A, nymphaeol-B, and nymphaeol-C.

Abstract: A process for the preparation of hydroxylated isoflavones by reacting in a Hoesch reaction using an alkanoic acid alkyl ester as solvent a phenol with a phenylacetonitrile to yield a 1,2-diphenyl-ethanone and transforming the ethanone into an isoflavone by well-known methods.

Abstract: The present invention relates to a method for resolution of a mixture of pinocembrin optical isomers, in particular a pinocembrin racemate, using a chiral primary amine or a chiral sulfinamide. The present invention also relates to a (R)-(+)-pinocembrin obtained by the method.

Abstract: A periodontal bacterial growth inhibitor contains as an active ingredient a Macaranga tanarius extract extracted from Macaranga tanarius with an extraction solvent including at least an organic solvent. Alternatively, the periodontal bacterial growth inhibitor contains as an active ingredient at least one selected from nymphaeol-A, nymphaeol-B, and nymphaeol-C. The periodontal bacterial growth inhibitor is used by being blended to, for example, an oral hygiene product or a food and drink.

Abstract: It is intended to provide a method for producing aglycone from a glycoside efficiently at low cost without using an acid catalyst or an organic solvent. The method for producing aglycone, characterized by bringing a glycoside into contact with high temperature high pressure water. The temperature of the high temperature high pressure water is generally from 100 to 374° C., preferably from 140 to 320° C., more preferably from 200 to 300° C. The pressure of the high temperature high pressure water may be not lower than the saturated water vapor pressure at the temperature, i.e., a pressure at which the liquid state is maintained.

Abstract: The disclosure relates to a new crystalline form of genistein. The disclosed crystalline form is crystalline genistein sodium salt dihydrate. The disclosure also relates to the novel genistein salt composition represented by this crystalline form. Therapeutic compositions containing crystalline genistein sodium salt and a pharmaceutically acceptable carrier are described. The disclosure also relates to therapeutic methods comprising the step of administering to a patient in need thereof a therapeutically effective amount of a therapeutic composition containing the crystalline form of the disclosure or crystalline genistein sodium salt dihydrate.

Abstract: The present invention relates to new prenylflavanone compounds and a pharmaceutical composition comprising at least one of the compounds.

Abstract: The present invention relates to new prenylflavanone compounds and a pharmaceutical composition comprising at least one of the compounds.

Abstract: The present invention provides compounds and methods of inhibiting and treating metastatic prostate cancer. The compounds include MEK4 inhibitors. In another aspect the invention provides methods of identifying inhibitors of metastatic prostate cancer by screening for inhibitors of MEK4.

Abstract: The present invention provides a 3?,4?,5-trimethoxy flavone derivative and a pharmaceutically acceptable salt thereof, preparation thereof, and a pharmaceutical composition for the treatment and prevention of dry eye syndrome comprising the same as an active ingredient. The 3?,4?,5-trimethoxy flavone derivative and its pharmaceutically acceptable salt inhibit corneal damage through excellent stimulatory action on mucus secretion in the conjunctiva and therefore may be effective as a prophylactic or therapeutic agent for dry eye syndrome.

Abstract: A composition suitable is disclosed for topical application for preventing and treating changes associated with skin aging and formation of abnormal skin lesions. The composition is derived by hydrolyzing a source composition in an acidic solution. The source composition can be, e.g., a soy composition and can include one or more isoflavones, phytoestrogens, sitosterols and saponins. After hydrolysis, water is added to the acidic solution to produce a first precipitate, which is then dissolved in an alcohol solution. The alcohol solution is then separated from undissolved portions of the first precipitate, and the alcohol in the separated alcohol solution is eliminated to produce a second precipitate of solids that were dissolved in the alcohol. This second precipitate is then dissolved in an organic solvent to produce a composition suitable for inclusion in a dermatological or cosmetic preparation.

Abstract: Provided is an antiviral agent with high antiviral activities and low side effects (cytotoxicity). Specifically provided is an antiviral agent comprising as an effective component at least one member selected from the group consisting of 5,7,4?-trihydroxy-3?,5?-dimethoxyflavone, 3-hydroxypyridine, p-hydroxybenzaldehyde and vanillin.

Abstract: Use of genistein for the treatment and prevention of dry eye syndrome or LKC and corresponding compositions containing it.

Abstract: The invention relates to a process for preparing 2,4-dihydroxyphenyl 4-methoxybenzyl ketones of the formula (I) by Friedel-Crafts acylation in hydrogen fluoride (HF). 2,4-Dihydroxyphenyl 4-methoxybenzyl ketones of the formula (I) in which R1 and R2 are each hydrogen, chlorine, fluorine, bromine, iodine, CF3, methyl, optionally substituted alkoxy, —OCF3, —C(CH3)3, —CH2(CH3)2, —CH(CH3)2, R3 is hydrogen, Cl, F, Br, optionally substituted alkyl, optionally substituted alkoxy, —C(CH3)3, and X is hydroxyl, F, Cl, Br, optionally substituted alkoxy, are obtained in high yield and high purity by reacting phenylacetic acid derivatives of the formula (II) with phenols of the formula (III) in liquid hydrogen fluoride (HF).

Abstract: Substituted flavonoid compounds, and pharmaceutical formulations of flavonoid compounds are described. Also described are processes for preparing flavonid compounds, as are methods for treating cancer in mammals using the described flavonoid compounds or pharmaceutical formulations thereof.

Abstract: A composition for treating cancer cells and a preparation method therefor are provided. The novel flavonoid compounds are obtained from natural plants, and more particularly the compounds have a cytotoxicity on cancer cells.